Primary Category:
Treatment Protocols
Disease Category:
Brain
Status:
Open
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
NCT#02523014
A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) are closed to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022.